Table 1 Baseline characteristics of kidney transplant patients according to Pneumocystis jirovecii pneumonia.
Variables | Non-PJP (n = 4,789) | PJP (n = 50) | P value |
|---|---|---|---|
Age at transplantation (years) | 49.1 ± 11.5 | 51.1 ± 13.6 | 0.102 |
Gender (female) | 1,945 (40.6%) | 20 (40.0%) | 0.930 |
Smoking | 0.180 | ||
Never | 3,633 (75.9%) | 37 (74.0%) | |
Current | 413 (8.6%) | 1 (2.0%) | |
Former | 691 (14.4%) | 11 (22.0%) | |
DM | 1,428 (29.8%) | 14 (28.0%) | 0.780 |
BMI (kg/m2) | 23.1 ± 0.10 | 21.80 ± 0.48 | 0.004 |
Hemoglobin (g/dL) | 10.79 ± 2.74 | 10.63 ± 1.93 | 0.579 |
Serum creatinine (mg/dL) | 1.29 ± 2.59 | 1.19 ± 0.39 | 0.169 |
eGFR (mL/min/1.73m2) | 38.11 ± 36.12 | 35.60 ± 31.55 | 0.625 |
Cause of ESRD | 0.282 | ||
DM, n (%) | 1,125 (23.5%) | 10 (20.0%) | |
Hypertension, n (%) | 757 (15.8%) | 6 (12.0%) | |
Glomerulonephritis, n (%) | 1,588 (33.2%) | 22 (44.0%) | |
Others, n (%) | 375 (7.8%) | 6 (12.0%) | |
Unknown, n (%) | 944 (19.7%) | 6 (12.0%) | |
Delayed graft function | 176 (3.6%) | 4 (8.0%) | 0.196 |
Re-transplantation, n (%) | 372 (7.8%) | 3 (6.0%) | 0.450 |
Type of donor | 0.289 | ||
Deceased donor, n (%) | 3,004 (62.1%) | 35 (70.0%) | |
Living donor, n (%) | 1,785 (36.9%) | 15 (30.0%) | |
Desensitization, n (%) | 1,083 (22.5%) | 19 (38.0%) | 0.011 |
Number of HLA mismatch | 3.2 ± 1.7 | 3.6 ± 1.4 | 0.104 |
Tacrolimus use at discharge, n (%) | 4,608 (96.2%) | 47 (94.0%) | 0.433 |
Tacrolimus dose at discharge (mg) | 5.96 ± 3.44 | 7.36 ± 4.62 | 0.014 |
Tacrolimus dose per body weight at discharge (mg/kg) | 0.10 ± 0.00 | 0.13 ± 0.01 | 0.001 |
Tacrolimus level at discharge (ng/mL) | 7.83 ± 0.05 | 8.05 ± 0.45 | 0.651 |
Formulation of tacrolimus | 0.629 | ||
Once daily, n (%) | 133 (2.7%) | 0 (0.0%) | |
Twice daily, n (%) | 4,104 (85.69%) | 37 (74%) | |
Unknown, n (%) | 371 (7.7%) | 10 (20%) | |
Tacrolimus conversion (twice to once daily), n (%) | 156 (3.87%) | 1 (3.03%) | 1.000 |
ATG use, n (%) | 998 (20.8%) | 7 (14%) | 0.236 |
Steroid use at discharge | 4,690 (97.93%) | 49 (98.0%) | 0.973 |
MMF use at discharge | 4,508 (94.13%) | 46 (92.0%) | 0.524 |
mTORi use at discharge | 51 (1.06%) | 2 (4.0%) | 0.047 |
PJP prophylaxis, n (%) | 4,626 (96.60%) | 50 (100.0%) | 0.184 |
Dose of prophylactic TMP-SMP, n (%) | 0.038 | ||
Single strength/d or double strength × 3/wk | 3,940 (82.27%) | 48 (96.0%) | |
Double strength/d | 686 (14.32%) | 2 (4.0%) | |
Duration of PJP prophylaxis (months) | 6.3 ± 2.6 | 6.0 ± 1.0 | 0.575 |
Mean follow up duration (months) | 24.93 ± 15.32 | 8.42 ± 7.57 | < 0.001 |
